These findings could open novel perspectives for drug-screening as well as future precision-medicine strategies in hereditary cancers and could be applied to other hereditary cancers as previously shown in BRCA1-mutated breast [5] and Li-Fraumeni-syndrome [3] and RET-mutated [2] cancers. This evidence concerns the gene RET and hereditary cancer.